Primary record
Salmeterol Xinafoate; (1RS)-1-[4-Hydroxy-3-(Hydroxymethyl)phenyl]-2-[[6-(4-phenylbutoxy)hexyl]amino]ethanol 1-hydroxynaphthalene-2-carboxylate; GR 33343G; GR 33343G
- 库存
- 9,762 克
- 纯度
- 98.6 %
- CAS
- 94749-08-3
化合物标识与属性
- CAS
- 94749-08-3
- PubChem CID
- 56801
- SMILES
- C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O
- Canonical SMILES
- O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O
名称与同义词
- salmeterol xinafoate
- Serevent
- Salmetedur
- 94749-08-3
- Arial
- Serevent diskus
- Betamican
- SALMETEROLO
- Ultrabeta
- Asmerole
- Dilamax
- Inaspir
- Beglan
- Siduomi
- Salmeterolxinafoate
- Salmetedur;
- Betamican;
- Aeromax;
- Inaspir;
- Beglan;
- Arial;
- Salmeterol xinafonate
- Serevent (TN)
- Salmeterol (xinafoate)
- GR 33343X xinafoate
- Salmeterol 1-hydroxy-2-naphthoate
- Salmeterol xinafoate?
- Xinafoate, Salmeterol
- Serevent Inhaler and Disks
- Salmeterol xinafoate [USAN]
- RefChem:56524
- Salmeterol xinafoate CRS
- AC1L1LPS
- GR 33343 G
- DTXSID1045798
- gr-33343g
- MFCD00897708
- Advair Diskus 100/50
- Advair Diskus 250/50
- Advair Diskus 500/50
- Salmeterol Hydroxynaphthoate
- UNII-6EW8Q962A5
- 6EW8Q962A5
- SCHEMBL18070
- DTXCID9025798
- C36H45NO7
- MLS001332577
- MLS001332578
- Salmeterol xinafoate [USAN:USP]
- CHEBI:9012
- LIPO-202
- orb1300582
- SCHEMBL2833182
- CHEMBL1082607
- GR-33343 G
- salmeterol, 1-hydroxy-2-naphthoate
- SCHEMBL29352164
- SCHEMBL29372524
- C25H37NO4.C11H8O3
- CTK8B9015
- Salmeterol xinafoate (JAN/USP)
- 94749-08-3 (xinafoate)
- GR-33343X
- XTZNCVSCVHTPAI-UHFFFAOYSA-N
- HMS2232I16
- HMS3263K22
- HMS3676P13
- HMS3749I03
- HMS3885J19
- HMS5083C07
- Salmeterol (xinafoate) (Standard)
- SALMETEROL XINAFOATE [JAN]
- AMY23373
- BCP04778
- CID56801
- GR 3343G
- Salmeterol 1-hydr oxy-2-naphthoate
- SALMETEROL XINAFOATE [VANDF]
- Tox21_111270
- Tox21_501100
- ANW-61823
- EBC-97122
- GR 33343G
- HY-17453R
- MSK000735
- NCGC00094372-03
- s4296
- SALMETEROL XINAFOATE [MART.]
- SN 408
- SALMETEROL XINAFOATE [USP-RS]
- SALMETEROL XINAFOATE [WHO-DD]
- AKOS016004957
- Tox21_111270_1
- 4-(1-Hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate
- ACN-040066
- AN-8181
- CCG-270203
- CS-1527
- FS27784
- KS-1140
- LP01100
- MSK000735-100M
- ADVAIR COMPONENT SALMETEROL XINAFOATE
- NCGC00015938-05
- NCGC00094372-01
- NCGC00094372-02
- NCGC00094372-04
- NCGC00261785-01
- 4CA-1124
- BC208521
- HY-17453
- LS-94516
- SALMETEROL XINAFOATE [EP IMPURITY]
- SALMETEROL XINAFOATE [ORANGE BOOK]
- SMR000875207
- SY047289
- BCP0726000003
- SALMETEROL XINAFOATE [EP MONOGRAPH]
- 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acid
- AB0020656
- CAS-94749-08-3
- DB-057527
- SALMETEROL XINAFOATE [USP MONOGRAPH]
- TC-150568
- A3190
- C25-H37-N-O4.C11-H8-O3
- EU-0101100
- FT-0642283
- NS00076193
- ST24031610
- V1621
- Salmeterol xinafoate, >=98% (HPLC), solid
- D00687
- LIPO-102 COMPONENT SALMETEROL XINAFOATE
- R10007
- SALMETEROL 1-HYDROXY-2-NAPHTHOATE [MI]
- Salmeterol xinafoate for system suitability CRS
- W-5199
- ADVAIR HFA COMPONENT SALMETEROL XINAFOATE
- AIRDUO RESPICLICK COMPONENT SALMETEROL XINAFOATE
- Salmeterol xinafoate for peak identification CRS
- A916443
- SR-01000597359
- SR-01000597359-1
- Q27264747
- Salmeterol Xinafoate Solution in Methanol, 100ug/mL
- B0084-079988
- (+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
- Salmeterol xinafoate, European Pharmacopoeia (EP) Reference Standard
- (+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
- 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
- 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; 1-hydroxynaphthalene-2-carboxylic acid
- Salmeterol xinafoate, United States Pharmacopeia (USP) Reference Standard
- Salmeterol xinafoate for system suitability, European Pharmacopoeia (EP) Reference Standard
- Salmeterol Xinafoate, Pharmaceutical Secondary Standards; Certified Reference Material
- ( inverted exclamation markA) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
- (+/-)-4-HYDROXY-.ALPHA.(SUP 1)-(((6-(4-PHENYLBUTOXY)HEXYL)AMINO)METHYL)-M-XYLENE-.ALPHA.,.ALPHA.'-DIOL 1-HYDROXY-2-NAPHTHOATE
- 1,3-BENZENEDIMETHANOL, 4-HYDROXY-.ALPHA.(SUP 1)-(((6-(4-PHENYLBUTOXY)HEXYL)AMINO)METHYL)-, (+/-)-, 1-HYDROXY-2-NAPHTHALENECARBOXYLATE
- 1-Hydroxynaphthalene-2-carboxylic acid--2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol (1/1)
- 2-(Hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol 1-hydroxy-2-naphthoate
- 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol,1-hydroxynaphthalene-2-carboxylic acid
- 4-[1-Hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-(hydroxymethyl)phenol 1-Hydroxy-2-naphthoate
- 4-[1-Hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-(hydroxymethyl)phenol compd. with 1-Hydroxy-2-naphthoic Acid (1:1)
- 4-Hydroxy-?1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic acid
- 4-Hydroxy-?1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic acid salt
- 4-Hydroxy-|A1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-Hydroxy-2-naphthalenecarboxylic Acid
- Salmeterol Xinafoate; (1RS)-1-[4-Hydroxy-3-(Hydroxymethyl)phenyl]-2-[[6-(4-phenylbutoxy)hexyl]amino]ethanol 1-hydroxynaphthalene-2-carboxylate; GR 33343G; GR 33343G